睿知中国医院研究地图
候选清单

杭州

浙江省人民医院

Zhejiang Provincial People's Hospital

在本站收录的 61 种疾病中,这家医院列在其中 27 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

浙江省人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma4 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma119 篇牵头论文
  4. 胃癌Stomach cancer38 篇牵头论文
  5. 肺癌Lung cancer69 篇牵头论文牵头 1 项开放试验
  6. 胰腺癌Pancreatic cancer53 篇牵头论文牵头 3 项开放试验
  7. 乳腺癌Breast cancer74 篇牵头论文牵头 1 项开放试验
  8. 胶质瘤Glioma24 篇牵头论文牵头 1 项开放试验
  9. 视网膜母细胞瘤Retinoblastoma0 篇牵头论文
  10. 骨肉瘤Osteosarcoma4 篇牵头论文
  11. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  12. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  13. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  14. 多发性骨髓瘤Multiple myeloma10 篇牵头论文
  15. 淋巴瘤Lymphoma15 篇牵头论文牵头 1 项开放试验
  16. 重症肌无力Myasthenia gravis2 篇牵头论文
  17. 冠心病Coronary heart disease12 篇牵头论文
  18. 先天性心脏病Congenital heart disease5 篇牵头论文
  19. 脊柱侧弯Scoliosis3 篇牵头论文
  20. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  21. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  22. 法布雷病Fabry disease1 篇牵头论文
  23. 杜氏肌营养不良Duchenne muscular dystrophy0 篇牵头论文
  24. 白塞病Behçet disease0 篇牵头论文
  25. IgA 肾病IgA nephropathy4 篇牵头论文
  26. 原发性胆汁性胆管炎Primary biliary cholangitis4 篇牵头论文
  27. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文

未列出的收录疾病:肝母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    发布
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 3320242025: 002025

杭州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题分子标志物与基因免疫治疗新辅助与综合治疗
论文中的科室放疗科
牵头的论文4
  1. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.2024BMC cancer免费全文
  2. Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.2024Biomolecules & biomedicine免费全文
  3. Annexin A2 combined with TTK accelerates esophageal cancer progression via the Akt/mTOR signaling pathway.2024Cell death & disease免费全文
  4. Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review).2023Oncology reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
PubMed 以外找到的论文(未计入)12
  1. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physics论文
  2. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Research会议摘要
  3. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  4. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncology会议摘要
  5. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncology会议摘要
  6. Effect of PLCE1-driven aerobic glycolysis through ENO1 modulation on immune evasion in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  7. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncology论文
  8. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncology论文
  9. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology论文
  10. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncology会议摘要
  11. P-104 Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncology会议摘要
  12. Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma via ZEB22022Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 119 篇,占 0.8%。

牵头论文
119
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 232320222023: 212120232024: 282820242025: 24242025

杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科病理/检验科消化/肝病科影像/核医学科
牵头的论文119
  1. Development and validation of machine learning-based model for predicting early recurrence for patients with HBV-associated hepatocellular carcinoma after curative hepatectomy.2026American journal of surgery
  2. Hepatic stellate cells shape the ECM-disorganized and immunosuppressive microenvironment via CCL11/CCR3 axis in lenvatinib-treated hepatocellular carcinoma.2026Cellular signalling
  3. Development and validation of a personalized web-based calculator of aggressive recurrence after surgery for early-stage hepatocellular carcinoma by machine learning.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. A non-invasive decision tree predicting recurrence-free survival after liver transplantation for hepatocellular carcinoma.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  5. Tumor-Targeted PLGA Nanospheres Enhance Therapeutic Effect of Lenvatinib in Hepatocellular Carcinoma via Photothermal and Photodynamic Therapy.2025ACS applied materials & interfaces
  6. Cancer Cell-Derived Exosomal miR-500a-3p Modulates Hepatic Stellate Cell Activation and the Immunosuppressive Microenvironment.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  7. Transcription factor FOXC2 regulates miR-145/ADAMTS5 axis to inhibit angiogenesis in hepatocellular carcinoma via circular RNA 0002898.2025BMC cancer免费全文
  8. Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.2025BMC cancer免费全文
  9. Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC.2025BMC cancer免费全文
  10. Developing a novel predictive model for identifying risk factors associated with being lost to follow-up among high-risk patients for recurrence following radical resection of hepatocellular carcinoma: the first report.2025BMC cancer免费全文
  11. Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review.2025BMC surgery免费全文
  12. Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.2025Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  13. RSK2-mediated phosphorylation and degradation of UBE2O inhibits hepatocellular carcinoma growth and resistance to radiotherapy.2025Cancer letters
  14. YY1 induced USP13 transcriptional activation drives the malignant progression of hepatocellular carcinoma by deubiquitinating WWP1.2025Cellular & molecular biology letters免费全文
  15. IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression.2025Cellular signalling
  16. Targeting Glycolytic Enzymes with 3-Bromopyruvic Acid to Enhance the Efficacy of Interventional Embolization in Hepatocellular Carcinoma.2025Current medical science
  17. Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Outcomes and risk factors for liver transplantation using steatotic grafts for hepatocellular carcinoma: a multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  19. Dual-Mode Treatment of Hepatocellular Carcinoma Using RGD Cyclopeptide-Modified Liposomes Loaded with Ce6/DOX.2025International journal of nanomedicine免费全文
  20. Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1/PD-L1 signalling.2025Journal of advanced research免费全文
  21. Tumor-microenvironment responsive nanomodulator for near infrared photothermal immunotherapy of hepatocellular carcinoma.2025Journal of nanobiotechnology免费全文
  22. Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria.2025Nature communications免费全文
  23. Perioperative and long-term outcomes of laparoscopic liver resection for combined hepatocellular carcinoma and cholangiocarcinoma versus intrahepatic cholangiocarcinoma: A propensity score matching analysis.2025PloS one免费全文
  24. The value of prealbumin in predicting post hepatectomy liver failure for patients with hepatocellular carcinoma undergoing major hepatectomy.2025Scientific reports免费全文
  25. Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.2025Scientific reports免费全文
  26. Radiomics analysis based on dynamic contrast-enhanced MRI for predicting early recurrence after hepatectomy in hepatocellular carcinoma patients.2025Scientific reports免费全文
  27. Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  28. Prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma through ultrasound elastography.2025World journal of gastroenterology免费全文
  29. Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  30. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.2024American journal of physiology. Cell physiology
  31. Development and validation of prealbumin-bilirubin score (preALBI score) for predicting long-term survival after hepatectomy for hepatocellular carcinoma: A multicenter analysis versus ALBI score.2024American journal of surgery
  32. The Prognostic Value of Preoperative Serum Markers and Risk Classification in Patients with Hepatocellular Carcinoma.2024Annals of surgical oncology
  33. Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.2024Asian journal of surgery
  34. Establishment of a novel ferroptosis-correlative lncRNA signature and validation of ST3GAL4-AS1 for predicting overall survival of hepatocellular carcinoma.2024Asian journal of surgery
  35. Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy.2024BMC cancer免费全文
  36. Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis.2024BMC cancer免费全文
  37. Comparison of percutaneous microwave/radiofrequency ablation liver partition and portal vein embolization versus transarterial chemoembolization and portal vein embolization for planned hepatectomy with insufficient future liver remnant.2024BMC cancer免费全文
  38. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.2024Biochemical and biophysical research communications
  39. FAM188B promotes the growth, metastasis, and invasion of hepatocellular carcinoma by targeting the hnRNPA1/PKM2 axis.2024Biochimica et biophysica acta. Molecular cell research
  40. UCHL3 promotes hepatocellular carcinoma progression by stabilizing EEF1A1 through deubiquitination.2024Biology direct免费全文
  41. OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1.2024Biology direct免费全文
  42. USP40 promotes hepatocellular carcinoma cell proliferation, migration and stemness by deubiquitinating and stabilizing Claudin1.2024Biology direct免费全文
  43. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.2024Cancer biology & medicine免费全文
  44. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.2024Expert opinion on drug metabolism & toxicology
  45. Multicenter propensity score-matched analysis to compare perioperative morbidity after laparoscopic or robotic complex hepatectomy for solitary hepatocellular carcinoma.2024HPB : the official journal of the International Hepato Pancreato Biliary Association
  46. Mild photothermal activation of TRPV1 pathway for enhanced calcium ion overload therapy of hepatocellular carcinoma.2024International journal of biological macromolecules
  47. Unveiling the Role of Mechanical Microenvironment in Hepatocellular Carcinoma: Molecular Mechanisms and Implications for Therapeutic Strategies.2024International journal of biological sciences免费全文
  48. Black Phosphorus Nanosheets-Loaded Single-Atom Gold Nanoenzymes for Enhanced Photodynamic Therapy of Hepatocellular Carcinoma.2024International journal of nanomedicine免费全文
  49. Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.2024International journal of surgery (London, England)免费全文
  50. Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.2024Journal of cachexia, sarcopenia and muscle免费全文
  51. LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF-1α-Dependent Glucose Metabolic Reprogramming.2024Journal of cellular and molecular medicine免费全文
  52. Letter to the editor: 'A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma'.2024Liver international : official journal of the International Association for the Study of the Liver
  53. Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.2024Molecular medicine (Cambridge, Mass.)免费全文
  54. Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis.2024Redox biology免费全文
  55. The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma.2024Signal transduction and targeted therapy免费全文
  56. Letter to the editor: "Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results".2024Surgery
  57. Comprehensive analysis of cell death genes in hepatocellular carcinoma based on multi-omics data.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  58. Comparison of diagnostic performance of AFP, DCP and two diagnostic models in hepatocellular carcinoma: a retrospective study.2023Annals of hepatology
  59. Pure laparoscopic resection of a large caudate-lobe mass guided by three-dimensional reconstruction and green fluorescence navigation.2023Asian journal of surgery
  60. Prognostic value of platelet distribution width to lymphocyte ratio in patients with hepatocellular carcinoma following hepatectomy.2023BMC cancer免费全文
  61. MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.2023BMC cancer免费全文
  62. UBE2K promotes the malignant progression of hepatocellular carcinoma by regulating c-Myc.2023Biochemical and biophysical research communications
  63. Polydopamine-Modified Zeolite Imidazole Framework Drug Delivery System for Photothermal Chemotherapy of Hepatocellular Carcinoma.2023Biomacromolecules
  64. Upregulation of MED7 was associated with progression in hepatocellular carcinoma.2023Cancer biomarkers : section A of Disease markers免费全文
  65. The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.2023Clinics and research in hepatology and gastroenterology
  66. Exosomal miR-374c-5p derived from mesenchymal stem cells suppresses epithelial-mesenchymal transition of hepatocellular carcinoma via the LIMK1-Wnt/β-catenin axis.2023Environmental toxicology
  67. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.2023Expert review of gastroenterology & hepatology
  68. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  69. Transcatheter arterial chemoembolization after percutaneous microwave ablation and portal vein embolization for advanced hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  70. Association of severity in the grading of microvascular invasion with long-term oncological prognosis after liver resection for early-stage hepatocellular carcinoma: a multicenter retrospective cohort study from a hepatitis B virus-endemic 2023International journal of surgery (London, England)免费全文
  71. Five machine learning-based radiomics models for preoperative prediction of histological grade in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  72. Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.2023Journal of physiology and biochemistry
  73. Hypoxia-induced UBE2K promotes the malignant progression of HCC.2023Pathology, research and practice
  74. LncRNA FRMD6-AS1 promotes hepatocellular carcinoma cell migration and stemness by regulating SENP1/HIF-1α axis.2023Pathology, research and practice
  75. A novel metabolism-related gene signature in patients with hepatocellular carcinoma.2023PeerJ免费全文
  76. Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study.2023Surgery today
  77. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.2023World journal of gastroenterology免费全文
  78. Editorial: non-viral hepatocellular carcinoma surveillance-an increasingly severe public health issue.2022Alimentary pharmacology & therapeutics
  79. Letter: sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.2022Alimentary pharmacology & therapeutics
  80. Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis.2022BMC infectious diseases免费全文
  81. Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1.2022Bioengineered免费全文
  82. Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.2022Cancer biology & therapy免费全文
  83. High expression of PPM1G is associated with the progression and poor prognosis of hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markers免费全文
  84. Resistance of Lenvatinib in Hepatocellular Carcinoma.2022Current cancer drug targets
  85. Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  86. Impact of diabetes mellitus on the long-term prognosis of patients with hepatocellular carcinoma after hepatectomy.2022Expert review of gastroenterology & hepatology
  87. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.2022Gene
  88. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty live2022Hepatobiliary & pancreatic diseases international : HBPD INT
  89. LncRNA ALKBH3-AS1 enhances ALKBH3 mRNA stability to promote hepatocellular carcinoma cell proliferation and invasion.2022Journal of cellular and molecular medicine免费全文
  90. Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.2022Journal of hepatology
  91. HBsAg seroclearance and reduction in late recurrence of HBV-related HCC: Causality or co-existence?2022Journal of hepatology
  92. Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.2022Journal of hepatology
  93. Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?2022Journal of hepatology
  94. The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.2022Journal of hepatology
  95. The updated BCLC staging system needs further refinement: A surgeon's perspective.2022Journal of hepatology
  96. The correlation of fibrinogen-like protein-1 expression with the progression and prognosis of hepatocellular carcinoma.2022Molecular biology reports免费全文
  97. PHF21A expression as a biomarker of hepatocellular carcinoma progression and prognosis.2022Neoplasma
  98. Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.2022Oncology research免费全文
  99. Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.2022Scientific reports免费全文
  100. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.2022The lancet. Gastroenterology & hepatology
  101. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model.2021Acta biochimica et biophysica Sinica
  102. Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from a hepatitis B virus-endemic area.2021American journal of surgery
  103. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma.2021BMC cancer免费全文
  104. Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis.2021BioMed research international免费全文
  105. HIF-1α-activated TM4SF1-AS1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by enhancing TM4SF1 expression.2021Biochemical and biophysical research communications
  106. An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation.2021Computational and mathematical methods in medicine免费全文
  107. Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  108. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.2021Hepatology international
  109. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.2021International journal of medical sciences免费全文
  110. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.2021Journal of hematology & oncology免费全文
  111. Comment on: Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  112. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.2021Pathology, research and practice
  113. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.2021Redox biology免费全文
  114. High expression of YKT6 associated with progression and poor prognosis of hepatocellular carcinoma.2021Scandinavian journal of gastroenterology
  115. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy.2021Small (Weinheim an der Bergstrasse, Germany)
  116. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management.2021Small (Weinheim an der Bergstrasse, Germany)
  117. The Clinical Significance of RMI2 in Hepatocellular Carcinoma.2021Technology in cancer research & treatment免费全文
  118. Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma.2021Technology in cancer research & treatment免费全文
  119. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.2021World journal of gastroenterology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  2. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  3. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 38 篇,占 0.4%。

牵头论文
38
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 4420222023: 5520232024: 111120242025: 992025

杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物腹膜转移与晚期早期发现与内镜
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文38
  1. Prediction model based on gut microbiota as a non-invasive tool for gastric cancer diagnosis.2025Applied microbiology and biotechnology免费全文
  2. ASPN was higher expression in gastric cancer and associated with poor prognosis through promoting invasion and migration and inducing macrophage M2 polarization.2025BMC cancer免费全文
  3. Histone lactylation drives METTL3 upregulation-mediated RNA m6A modification of CCT2 to hinder CD8+ T cell survival in gastric cancer.2025Cellular and molecular life sciences : CMLS免费全文
  4. Integrated analysis of single-cell and bulk transcriptomes reveals the prognostic value of polyamine metabolism biomarkers and immune microenvironment features in gastric cancer.2025Frontiers in immunology免费全文
  5. NRAV promoted the malignant progression of gastric cancer.2025Gene
  6. FGL1 facilitates rather than suppresses anticancer immunity against microsatellite instable gastric cancer.2025Genes and immunity
  7. PICK1 modulates the proliferation and migration of gastric cancer cells by regulating TLR4.2025Journal of Zhejiang University. Science. B免费全文
  8. The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.2025Neuroendocrinology
  9. Explore the role of CBS in stomach adenocarcinoma based on the sulfur-containing amino acid metabolism network.2025Scientific reports免费全文
  10. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer.2024Annals of nuclear medicine免费全文
  11. M6A methylation of FKFB3 reduced pyroptosis of gastric cancer by NLRP3.2024Anti-cancer drugs
  12. RARB associated with MSI, affects progression and prognosis of gastric cancer.2024BMC gastroenterology免费全文
  13. A prognostic risk model based on lactate metabolism and transport-related lncRNAs for gastric adenocarcinoma.2024Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  14. WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα.2024Cancer biology & therapy免费全文
  15. WYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway.2024European journal of pharmacology
  16. F2RL3 Regulates Epithelial-Mesenchymal Transition and Angiogenesis in Gastric Cancer through the Rap1/MAPK Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  17. Weifuchun suppresses the malignancy of gastric cancer cells by targeting KPNA2 through miR-26a-5p-mediated destabilization and the deactivation of the MAPK signaling pathway.2024Journal of ethnopharmacology
  18. Galectin-1 Promotes Gastric Carcinoma Progression and Cisplatin Resistance Through the NRP-1/c-JUN/Wee1 Pathway.2024Journal of gastric cancer免费全文
  19. KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner.2024Journal of translational medicine免费全文
  20. The efficacy and safety of per-nasal "GTS partner" assisted traction technique for gastric endoscopic submucosal dissection: a prospective single-center randomized clinical trial.2024Surgical endoscopyRCT免费全文
  21. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.2023Cancer medicine免费全文
  22. KCND2: A prognostic biomarker and regulator of immune function in gastric cancer.2023Cancer medicine免费全文
  23. Helicobacter pylori Infection as a Predictor of Treatment Outcomes of Gastric Cancer: A Systematic Review and Meta-Analysis.2023Digestive diseases (Basel, Switzerland)
  24. Competing endogenous RNA network characterization of lymph node metastases in Leuran gastric cancer subtypes.2023Journal of cancer research and clinical oncology免费全文
  25. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.2023World journal of surgical oncology免费全文
  26. Clinicopathological study of gastric schwannoma and review of related literature.2022BMC surgery免费全文
  27. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor.2022Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  28. Identification of three immune subtypes characterized by distinct tumor immune microenvironment and therapeutic response in stomach adenocarcinoma.2022Gene
  29. TLR4 rs4986790 polymorphism confers risk to Helicobacter pylori infection in Zhejiang, China and its enlightenment to nursing care.2022Journal of clinical laboratory analysis免费全文
  30. Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer.2021Applied microbiology and biotechnology
  31. Circular RNA circCOL6A3_030 is involved in the metastasis of gastric cancer by encoding polypeptide.2021Bioengineered免费全文
  32. Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.2021Bioengineered免费全文
  33. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.2021Cancer control : journal of the Moffitt Cancer Center免费全文
  34. Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2.2021Computational and mathematical methods in medicine免费全文
  35. Protein interacting with C-kinase 1 is involved in epithelial-mesenchymal transformation and suppresses progress of gastric cancer.2021Medical oncology (Northwood, London, England)
  36. Evaluation of the efficiency and safety of combined chemotherapy and molecular-targeted therapy in the treatment of advanced gastric cancer: A protocol for systematic review and meta-analysis.2021Medicine免费全文
  37. RORβ suppresses the stemness of gastric cancer cells by downregulating the activity of the Wnt signaling pathway.2021Oncology reports免费全文
  38. Immunotherapy of gastric cancer: Past, future perspective and challenges.2021Pathology, research and practice
中文论文(未计入)2
  1. [Clinical application of complete laparoscopic gastrectomy with function preservation of cardia in gastric carcinoma].2022Zhonghua yi xue za zhi
  2. [Integrin α5 promotes the proliferation, invasion and adhesion of gastric cancer by regulating the FAK/Src/Rac1 signaling pathway].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer已完成NCT06464965牵头方I期2024-07 启动
  2. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  3. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  4. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma已终止NCT04718402研究中心I期2021-03 启动
  5. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  7. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  8. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 69 篇,占 0.3%。

牵头论文
69
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 141420222023: 151520232024: 141420242025: 18182025

杭州有 11 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06534762

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江省人民医院杭州

  2. 正在招募
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06890598

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙

  3. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、济南、石家庄、襄阳、贵阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室放疗科影像/核医学科肿瘤内科病理/检验科
牵头的论文69
  1. A KAT7-lncPVT1 positive feedback loop promotes lung cancer carcinogenesis and therapy resistance via H3K14ac/HDGF/PI3K/AKT Axis.2026International journal of biological macromolecules
  2. Analysis of setup error and setup efficiency in SBRT for non-small cell lung cancer via a surface-guided radiation therapy system.2025BMC cancer免费全文
  3. Utilization of artificial intelligence-based pulmonary nodule target reconstruction software in clinical practice education for standardized training residents.2025BMC medical education免费全文
  4. LINC01214 Promotes Non-Small Cell Lung Cancer Through the miR-497-3p/HSP90AB1 Axis.2025Canadian respiratory journal免费全文
  5. DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.2025Cancer immunology, immunotherapy : CII免费全文
  6. COL5A2-mediated endoplasmic reticulum stress promotes macrophage M2 polarization in lung adenocarcinoma.2025Cell stress & chaperones免费全文
  7. LZTS3 represses tumorigenesis and radioresistance via CK1δ and β-TrCP-mediated ubiquitination pathway in lung cancer.2025Cellular signalling
  8. Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.2025Clinica chimica acta; international journal of clinical chemistry
  9. MCOLN1-Mediated Endoplasmic Reticulum Stress Induces Autophagy to Facilitate Lung Cancer Growth, Migration, and Invasion.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  10. Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial.2025Journal of affective disordersRCT
  11. USP28-mediated deubiquitination of FOXK1 activates the Hippo signaling pathway to regulate cell proliferation and radiosensitivity in lung cancer.2025Life sciences
  12. Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.2025Lung cancer (Amsterdam, Netherlands)
  13. Temozolomide and anlotinib as second-line therapy for non-small cell lung cancer patients with brain metastases: a retrospective cohort study.2025Neoplasma
  14. Comparative dosimetric evaluation of single-beam dual-arc versus dual-beam single-arc volumetric modulated arc therapy strategies in lung stereotactic body radiotherapy using Monaco.2025PeerJ免费全文
  15. A retrospective study of automatic progressive optimization for lung cancer radiotherapy plans on the Halcyon and RayStation systems.2025PeerJ免费全文
  16. Poricoic Acid A, an Active Ingredient Extracted From Poria cocos, Inhibits Lung Cancer Cell Growth by Suppressing MEK/ERK Signaling Pathway.2025Phytotherapy research : PTR
  17. Dosimetric comparison of Monte Carlo, Acuros XB, and anisotropic analytical algorithm for lung cancer plans on halcyon accelerators.2025PloS one免费全文
  18. Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.2025PloS one免费全文
  19. Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function.2025Scientific reports免费全文
  20. Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway.2024BMB reports免费全文
  21. Impact of immunosuppressants on tumor pulmonary metastasis: new insight into transplantation for hepatocellular carcinoma.2024Cancer biology & medicine免费全文
  22. COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma.2024Cell death & disease免费全文
  23. A clinical-radiological predictive model for solitary pulmonary nodules and the relationship between radiological features and pathological subtype.2024Clinical radiology
  24. Re: peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.2024Clinical radiology
  25. NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung Adenocarcinoma via MYC Translational Activation.2024Combinatorial chemistry & high throughput screening
  26. microRNA-486-5p Regulates DNA Damage Inhibition and Cisplatin Resistance in Lung Adenocarcinoma by Targeting AURKB.2024Critical reviews in eukaryotic gene expression
  27. Sanguinarine Attenuates Lung Cancer Progression via Oxidative Stress-induced Cell Apoptosis.2024Current molecular pharmacology
  28. Hypoxia A Typical Target in Human Lung Cancer Therapy.2024Current protein & peptide science
  29. Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study.2024Journal of proteome research
  30. Pan-cancer landscape analysis of NOP58 and its oncogenic driving role in lung adenocarcinoma.2024Scientific reports免费全文
  31. Multi-instance learning based lung nodule system for assessment of CT quality after small-field-of-view reconstruction.2024Scientific reports免费全文
  32. A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.2024Therapeutic advances in respiratory disease免费全文
  33. Prognostic value of lymph node metrics in lung squamous cell carcinoma: an analysis of the SEER database.2024World journal of surgical oncology免费全文
  34. Promotion of Lung Cancer Metastasis by SIRT2-Mediated Extracellular Protein Deacetylation.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  35. Diosbulbin C, a novel active ingredient in Dioscorea bulbifera L. extract, inhibits lung cancer cell proliferation by inducing G0/G1 phase cell cycle arrest.2023BMC complementary medicine and therapies免费全文
  36. SIRP-alpha-IL-6 axis induces immunosuppressive macrophages in non-small-cell lung cancer.2023Biochemical and biophysical research communications
  37. The roles, molecular interactions, and therapeutic value of CDK16 in human cancers.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  38. Thirdhand Smoke May Promote Lung Adenocarcinoma Development through HN1.2023Computational and mathematical methods in medicine免费全文
  39. 68Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging.2023European journal of nuclear medicine and molecular imaging免费全文
  40. Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma.2023Frontiers in immunology免费全文
  41. Case report: Interstitial lung disease of XELOEX chemotherapy with cetuximab in advanced colon cancer induced.2023Medicine免费全文
  42. A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers.2023Medicine免费全文
  43. Molecular characterization of genomic breakpoints of ALK rearrangements in non-small cell lung cancer.2023Molecular oncology免费全文
  44. Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study.2023Molecular oncology免费全文
  45. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.2023PeerJ免费全文
  46. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.2023Scientific reports免费全文
  47. Circ_MACF1 targets miR-421 to upregulate FMO2 to suppress paclitaxel resistance and malignant cellular behaviors in lung adenocarcinoma.2023Thoracic cancer免费全文
  48. Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.2023Ultrastructural pathology
  49. Development of Deep Learning-based Automatic Scan Range Setting Model for Lung Cancer Screening Low-dose CT Imaging.2022Academic radiology
  50. TECPR1 Induces Apoptosis in Non-Small Cell Lung Carcinoma via ATG5 Upregulation-Induced Autophagy Promotion.2022Annals of clinical and laboratory science
  51. The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.2022BMC cancer免费全文
  52. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.2022BMC pulmonary medicine免费全文
  53. Knockdown of lncRNA PCAT6 suppresses the growth of non-small cell lung cancer cells by inhibiting macrophages M2 polarization via miR-326/KLF1 axis.2022Bioengineered免费全文
  54. Classification and Segmentation Algorithm in Benign and Malignant Pulmonary Nodules under Different CT Reconstruction.2022Computational and mathematical methods in medicine免费全文
  55. Novel immunotherapeutic drugs for the treatment of lung cancer.2022Current opinion in oncology
  56. Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.2022Frontiers in public health免费全文
  57. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.2022Journal of cancer research and therapeutics
  58. Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines.2022Life sciences
  59. Risk and Incidence of Infection with Bevacizumab in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis.2022Oncology research and treatment
  60. The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.2022PloS one免费全文
  61. Neoadjuvant immunotherapy for resectable hepatocellular carcinoma.2022The lancet. Gastroenterology & hepatology
  62. Down-regulation of CLEC3B facilitates epithelial-mesenchymal transition, migration and invasion of lung adenocarcinoma cells.2022Tissue & cell
  63. Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.2021BMC cancer免费全文
  64. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.2021Cell biochemistry and function免费全文
  65. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.2021Drug delivery免费全文
  66. MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation.2021Journal of applied genetics
  67. A comparative study of auto-contouring softwares in delineation of organs at risk in lung cancer and rectal cancer.2021Scientific reports免费全文
  68. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database.2021Scientific reports免费全文
  69. Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)1
  1. [Seromucinous hamartoma in the lung: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study正在招募NCT06534762牵头方II期2024-07 启动
  2. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer正在招募NCT06890598研究中心III期2025-03 启动
  3. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  4. A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC进行中,不再招募NCT05879068研究中心II期2022-05 启动
  5. Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer已完成NCT05014815研究中心II期2021-11 启动
  6. Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.已完成NCT05068427研究中心II期2021-11 启动
  7. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT04237805研究中心I/II期2016-11 启动
  8. Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease状态不明NCT01690390研究中心II期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 53 篇,占 0.9%。

牵头论文
53
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 101020222023: 6620232024: 8820242025: 14142025

杭州有 9 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07312422

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省人民医院杭州

  2. 正在招募
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06534762

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江省人民医院杭州

  3. 正在招募
    Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06722911

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:浙江省人民医院杭州

  4. 正在招募
    A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
    分期
    II期
    开始
    2025-12
    发布
    登记号
    NCT07255404

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、昆明、杭州、武汉、沈阳、郑州

  5. 正在招募
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    分期
    II/III期
    开始
    2024-05
    发布
    登记号
    NCT06361888

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、哈尔滨、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、海口、深圳、温州、福州、苏州、西安、郑州、重庆、长沙

  6. 正在招募
    A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
    分期
    II期
    开始
    2023-05
    发布
    登记号
    NCT05859750

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、广州、杭州、武汉、济南

  7. 正在招募
    A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
    分期
    I期
    开始
    2023-07
    发布
    登记号
    NCT05911217

    年龄 18 岁 至 79 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、北京、杭州、武汉、西安、郑州、长沙

  8. 正在招募
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    分期
    II期
    开始
    2023-10
    发布
    登记号
    NCT06008288

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、福州、西安、郑州、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室普外/肝胆胰外科病理/检验科肿瘤内科影像/核医学科
牵头的论文53
  1. Diagnostic performance of artificial intelligence based on contrast-enhanced computed tomography in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.2026Abdominal radiology (New York)
  2. 18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma.2026Academic radiology
  3. PIM1 protects pancreatic ductal cancer cells from glucose deprivation-induced oxidative stress via OXR1 phosphorylation.2026Biochimica et biophysica acta. Molecular basis of disease
  4. Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma.2026Cancer research and treatment免费全文
  5. The acidic microenvironment promotes pancreatic cancer progression via the lncRNA-LOC100507424/E2F1/FOXM1 axis.2025BMC cancer免费全文
  6. A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment.2025Cancer letters
  7. SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.2025Cancer medicine免费全文
  8. A clinically applicable machine learning model for personalized survival prediction in metastatic pancreatic neuroendocrine tumors.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Oncogenic Role of PTPN14 in Pancreatic Cancer Through β-Catenin/NF-κB Pathway Activation.2025IUBMB life
  10. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.2025Journal of gastroenterology
  11. Small bowel obstruction in patients associated with immune checkpoint inhibitors combined with chemotherapy: Two case reports and a review.2025Medicine免费全文
  12. The Causal Role of Gut Microbiota and Immune Cell Mediation in Gastroenteropancreatic Neuroendocrine Neoplasms: A Mendelian Randomization Study.2025Neuroendocrinology
  13. PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer.2025PeerJ免费全文
  14. TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade.2025Redox biology免费全文
  15. Predicting textbook outcome after pancreaticoduodenectomy for invasive intraductal papillary mucinous neoplasm: An international validation cohort study.2025Surgery
  16. β-hydroxybutyrate dehydrogenase promotes pancreatic cancer cell proliferation through regulation of the NAD+/NADH balance and mitochondrial acetylation.2025The Journal of biological chemistry免费全文
  17. Antioxidant capacity of the iron-sulfur cluster assembly protein IscU2 is mediated by aspartate metabolism to promote tumor survival.2025The Journal of biological chemistry免费全文
  18. Delayed gastric emptying risk stratification in patients with pancreatic ductal adenocarcinoma after pancreatoduodenectomy: An international validation cohort study.2025United European gastroenterology journal免费全文
  19. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.2024Biochimica et biophysica acta. Molecular basis of disease
  20. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  21. WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc.2024Cellular & molecular biology letters免费全文
  22. Single-cell transcriptomics reveal the prognostic roles of epithelial and T cells and DNA methylation-based prognostic models in pancreatic cancer.2024Clinical epigenetics免费全文
  23. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.2024Oncoimmunology免费全文
  24. Interpretable multitemporal liver function indicator model for prediction and risk factor analysis of drug induced liver injury.2024Scientific reports免费全文
  25. A smart tablet-phone-based high-performance pancreatic cancer cell biosensing system for drug screening.2024Talanta
  26. Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and pancreatic cancer.2024World journal of surgical oncology免费全文
  27. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study.2023BMC cancer免费全文
  28. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular.2023Cancer letters
  29. An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma.2023Frontiers in bioscience (Landmark edition)
  30. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  31. UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma.2023International journal of oncology免费全文
  32. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma.2023World journal of surgical oncology免费全文
  33. Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review.2022Anti-cancer drugs免费全文
  34. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?2022Anti-cancer drugs免费全文
  35. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.2022Bioengineered免费全文
  36. CT-based differentiation of solid pseudopapillary neoplasm and nonfunctional neuroendocrine tumor of pancreas.2022Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  37. Innate immunity in pancreatic cancer: Lineage tracing and function.2022Frontiers in immunology免费全文
  38. Two Novel Nomograms Predicting the Risk and Prognosis of Pancreatic Cancer Patients With Lung Metastases: A Population-Based Study.2022Frontiers in public health免费全文
  39. Algorithm-based care after pancreatic resection.2022Lancet (London, England)
  40. Laparoscopic duodenum-preserving pancreatic head resection with real-time indocyanine green guidance of different dosage and timing: enhanced safety with visualized biliary duct and its long-term metabolic morbidity.2022Langenbeck's archives of surgery免费全文
  41. Functions and clinical applications of exosomes in pancreatic cancer.2022Molecular biology reports免费全文
  42. PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  43. ASO Author Reflections: Innovative Techniques for Laparoscopic Duodenum-Preserving Pancreatic Head Resection.2021Annals of surgical oncology
  44. Laparoscopic radical antegrade modular pancreatosplenectomy: preliminary experience with 10 cases.2021BMC surgery免费全文
  45. Downregulation of long non-coding RNA LINC00460 inhibits the proliferation, migration and invasion, and promotes apoptosis of pancreatic cancer cells via modulation of the miR-320b/ARF1 axis.2021Bioengineered免费全文
  46. Radiomic nomogram based on MRI to predict grade of branching type intraductal papillary mucinous neoplasms of the pancreas: a multicenter study.2021Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  47. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.2021Cell death & disease免费全文
  48. Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis.2021Frontiers in endocrinology免费全文
  49. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.2021Frontiers in immunology免费全文
  50. The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways.2021Journal of cellular biochemistry
  51. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.2021Molecular and cellular biochemistry
  52. Comparison of clinical outcomes and quality of life between laparoscopic distal pancreatectomy with or without spleen preservation.2021Surgical endoscopy
  53. Adult pancreatoblastoma: a case report.2021The Journal of international medical research免费全文
中文论文(未计入)4
  1. [Clinical analysis of splenic circulation control technology applied in minimally invasive radical resection of pancreatic neck and body cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [The outcomes of robotic-assisted enucleation for tumors located in uncinate process of pancreas in 16 cases].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Innovation and development of surgical techniques for pancreatic tumors].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [Clinical effect of minimally invasive duodenum preserving pancreatic head resection for benign and pre-malignant lesions of pancreatic head].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study正在招募NCT07312422牵头方I/II期2025-09 启动
  2. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study正在招募NCT06534762牵头方II期2024-07 启动
  3. Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer正在招募NCT06722911牵头方II期2024-11 启动
  4. Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer已完成NCT06464965牵头方I期2024-07 启动
  5. Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo状态不明NCT05613465牵头方不分期2022-10 启动
  6. Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy状态不明NCT04810910牵头方I期2021-03 启动
  7. Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer已终止NCT03585062牵头方II期2017-11 启动
  8. Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer已完成NCT03645148牵头方I期2017-10 启动
  9. Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula已完成NCT02790333牵头方(推断)不分期2016-05 启动
  10. A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer正在招募NCT07255404研究中心II期2025-12 启动
  11. A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer正在招募NCT06361888研究中心II/III期2024-05 启动
  12. A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer正在招募NCT05859750研究中心II期2023-05 启动
  13. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.正在招募NCT06008288研究中心II期2023-10 启动
  14. A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer正在招募NCT05911217研究中心I期2023-07 启动
  15. A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer已完成NCT04228601研究中心I/II期2020-01 启动
  16. Laparoscopic vs Open Pancreatectomy for Body and Tail Pancreatic Cancer状态不明NCT03792932研究中心不分期2019-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 74 篇,占 0.4%。

牵头论文
74
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 121220222023: 181820232024: 121220242025: 23232025

杭州有 9 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06534762

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江省人民医院杭州

  2. 正在招募
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    分期
    III期
    开始
    2025-06
    发布
    登记号
    NCT06966700

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 21 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、合肥、哈尔滨、杭州、武汉、济南、西安、郑州、长春、长沙

  3. 正在招募
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    分期
    II期
    开始
    2024-11
    发布
    登记号
    NCT06452706

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、乌鲁木齐、哈尔滨、杭州、武汉、西安

  4. 正在招募
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    分期
    III期
    开始
    2023-10
    发布
    登记号
    NCT05696626

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 57 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、大连、天津、宁波、安阳、广州、徐州、成都、昆明、杭州、梅州、武汉、沈阳、泸州、洛阳、海口、深圳、温州、石家庄、福州、蚌埠、襄阳、西安、郑州、重庆、长春、长沙、青岛

  5. 正在招募
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    分期
    不分期
    开始
    2023-07
    发布
    登记号
    NCT07920094

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属邵逸夫医院;另有 10 家列出的医院为研究中心台州、宁波、杭州、温州、金华

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科放疗科肿瘤内科普外/肝胆胰外科
牵头的论文74
  1. UBE2K promotes breast cancer growth by ubiquitinating and degrading STUB1 to regulate the PKA/CREB1 signaling pathway, forming a feedback loop.2026Biochimica et biophysica acta. Molecular basis of disease
  2. Uncovering the symptom relationship among sleep quality, anxiety, and depression in Chinese patients with breast cancer: multidimensional data validation using PSQI versus actigraphy.2026Journal of cancer survivorship : research and practice
  3. Senescence-Inducing Therapy Sequential NIR-II Mild Photothermal/Senolytic Therapy of Triple Negative Breast Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple-Negative Breast Cancer Models.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Clinical Experience in the Management of the Polyacrylamide Hydrogel (PAAG) Associated Complications Including Four Breast Cancer Cases: A Retrospective Study of 135 Cases.2025Aesthetic plastic surgery
  6. Luminol/PtCo@rGO and Au@CNTs-based electrochemiluminescence cytosensor for ultrasensitive detection of breast cancer CTCs.2025Analytica chimica acta
  7. Development and validation of an 18F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study.2025Annals of nuclear medicine免费全文
  8. Trends in the global, national, and regional burden of breast cancer among adolescents and young adults from 1990 to 2021: Analyses of the 2021 global burden of disease study.2025Breast (Edinburgh, Scotland)免费全文
  9. Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.2025British journal of cancer免费全文
  10. Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.2025British journal of cancer免费全文
  11. Interpretable Machine Learning for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using the Baseline Clinical and Pathological Characteristics.2025Cancer medicine免费全文
  12. SCGB3A1-Epi and KLK10-Epi Crosstalk With Fibroblasts Promotes Liver Metastasis of Breast Cancer and Pancreatic Ductal Adenocarcinoma.2025Cancer medicine免费全文
  13. Breast Cancer in Working-Age Men: A Population-Based Investigation of Global, Regional, and National Disease Burdens Between 1990 and 2021.2025Clinical breast cancer
  14. Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling.2025Frontiers in immunology免费全文
  15. Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery.2025International immunopharmacology
  16. Integrative single-cell and bulk RNA sequencing of lactate metabolism identifies PDP-1 as a prognostic biomarker in breast cancer.2025International journal of biological macromolecules
  17. MR imaging of breast cancer: Interpretable radiomics analysis to assess treatment response and survival prognosis after neoadjuvant therapy.2025International journal of cancer
  18. Xihuang pill suppresses breast cancer malignancy by inhibiting TGF-β signaling and acquires chemotherapy benefits.2025Journal of ethnopharmacology
  19. Acetylation suppresses breast cancer progression by sustaining CLYBL stability.2025Journal of translational medicine免费全文
  20. Fibroblast Activation Protein (FAP)+ cancer-associated fibroblasts induce macrophage M2-like polarization via the Fibronectin 1-Integrin α5β1 axis in breast cancer.2025Oncogene
  21. Enhancing breast magnetic resonance imaging segmentation with a federated semi-supervised approach.2025Scientific reports免费全文
  22. Implication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy.2025Scientific reports免费全文
  23. Machine learning analysis of coagulation-related genes for breast cancer diagnosis and prognosis prediction.2025Scientific reports免费全文
  24. The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases.2025Scientific reports免费全文
  25. Tumor-colonizing Pseudoalteromonas elyakovii metabolically reprograms the tumor microenvironment and promotes breast ductal carcinoma.2025mBio免费全文
  26. 3D-Printed Breast Prosthesis that Smartly Senses and Targets Breast Cancer Relapse.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  27. Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue.2024BMC medical imaging免费全文
  28. Research progress in tumor angiogenesis and drug resistance in breast cancer.2024Cancer biology & medicine免费全文
  29. Acidosis activates breast cancer ferroptosis through ZFAND5/SLC3A2 signaling axis and elicits M1 macrophage polarization.2024Cancer letters
  30. Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients.2024Clinical breast cancer
  31. Whole transcriptome sequencing indicated the Anti-tumor immunity of NLRP3 in breast cancer.2024Genomics
  32. CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer.2024Journal of advanced research免费全文
  33. Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer patients: use of MRI radiomics data from three regions with multiple machine learning algorithms.2024Journal of cancer research and clinical oncology免费全文
  34. The crosstalk between benign thyroid disease and breast cancer: A single center study.2024Medicine免费全文
  35. Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy.2024Pharmacological research
  36. The role of adjuvant endocrine treatment in ER+, PR-, HER2- early breast cancer: a retrospective study of real-world data.2024Scientific reports免费全文
  37. Platelet Membrane Coated Cu9S8-SNAP for Targeting NIR-II Mild Photothermal Enhanced Chemodynamic/Gas Therapy of Triple-Negative Breast Cancer.2024Small (Weinheim an der Bergstrasse, Germany)
  38. Estimated cardiorespiratory fitness in relation to overall, breast and prostate cancer incidence: the Norwegian HUNT study.2023Annals of epidemiology
  39. Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.2023BMC cancer免费全文
  40. Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.2023BMC cancer免费全文
  41. Gut microbiome causal impacts on the prognosis of breast cancer: a Mendelian randomization study.2023BMC genomics免费全文
  42. Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217/G3BP2 signaling pathway.2023Breast cancer research : BCR免费全文
  43. Synthesis of poly (L-cysteine)/g-C3N4 modified glassy carbon electrodes for electrochemical detection of methotrexate as a medicine for treatment of breast cancer in pharmaceutical fluid samples.2023Chemosphere
  44. Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer.2023Chinese medical journal免费全文
  45. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.2023Chinese medical journal免费全文
  46. Establishing a Predictive Model to Predict Survival of de Novo Metastatic HER2-Low Breast Cancer: A National Cancer Database Analysis.2023Discovery medicine
  47. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.2023Frontiers in immunology免费全文
  48. Integrated analysis of FKBP1A/SLC3A2 axis in everolimus inducing ferroptosis of breast cancer and anti-proliferation of T lymphocyte.2023International journal of medical sciences免费全文
  49. Correlation between the setting of gating window width and setup accuracy in left breast cancer radiotherapy based on deep inspiration breath hold.2023Journal of applied clinical medical physics免费全文
  50. Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses.2023Journal of cancer research and clinical oncology免费全文
  51. NIR diagnostic imaging of triple-negative breast cancer and its lymph node metastasis for high-efficiency hypoxia-activated multimodal therapy.2023Journal of nanobiotechnology免费全文
  52. OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression.2023Pathology, research and practice
  53. Predicting diagnosis and survival of bone metastasis in breast cancer using machine learning.2023Scientific reports免费全文
  54. FKBP5 associated CD8 T cell infiltration is a novel prognostic biomarker in luminal B breast cancer.2023The Journal of international medical research免费全文
  55. Breast cancer organoids and their applications for precision cancer immunotherapy.2023World journal of surgical oncology免费全文
  56. Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer.2022Advanced healthcare materials
  57. Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.2022BMC cardiovascular disorders免费全文
  58. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.2022BMJ open免费全文
  59. Thyrotropin suppression therapy using levothyroxine does not negatively affect breast cancer prognosis.2022Cancer treatment and research communications
  60. Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery.2022Current medicinal chemistry
  61. Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.2022Frontiers in immunology免费全文
  62. miR-10b-5p-mediated upregulation of PIEZO1 predicts poor prognosis and links to purine metabolism in breast cancer.2022Genomics
  63. Autophagy-related prognostic signature for survival prediction of triple negative breast cancer.2022PeerJ免费全文
  64. Metastasis patterns and prognosis of octogenarians with metastatic breast cancer: A large-cohort retrospective study.2022PloS one免费全文
  65. Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.2022Radiation oncology (London, England)免费全文
  66. Breast metastasis of signet ring cell carcinoma from the colon: a case report.2022World journal of surgical oncology免费全文
  67. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective stu2022World journal of surgical oncology免费全文
  68. Integrative genomic analysis of N6-methyladenosine-single nucleotide polymorphisms (m6A-SNPs) associated with breast cancer.2021Bioengineered免费全文
  69. Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer.2021Cell death & disease免费全文
  70. Naringenin Regulates FKBP4/NR3C1/NRF2 Axis in Autophagy and Proliferation of Breast Cancer and Differentiation and Maturation of Dendritic Cell.2021Frontiers in immunology免费全文
  71. Role of immune regulatory cells in breast cancer: Foe or friend?2021International immunopharmacology
  72. Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway.2021Journal of translational medicine免费全文
  73. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.2021The Journal of international medical research免费全文
  74. Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer.2021World journal of surgical oncology免费全文
中文论文(未计入)2
  1. Estrogen upregulates DNA2 expression through the PI3K-AKT pathway in endometrial carcinoma.2023Journal of Zhejiang University. Science. B免费全文
  2. [Solid Tumors With Cold Agglutinins:Report of Two Cases and Literature Review].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study正在招募NCT06534762牵头方II期2024-07 启动
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)正在招募NCT06966700研究中心III期2025-06 启动
  3. The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer正在招募NCT06452706研究中心II期2024-11 启动
  4. Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery正在招募NCT07920094研究中心不分期2023-07 启动
  5. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation正在招募NCT05696626研究中心III期2023-10 启动
  6. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)进行中,不再招募NCT06680921研究中心III期2024-11 启动
  7. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer进行中,不再招募NCT05346224研究中心III期2022-04 启动
  8. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)进行中,不再招募NCT05296798研究中心III期2022-07 启动
  9. A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer进行中,不再招募NCT05514054研究中心III期2022-10 启动
  10. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer状态不明NCT05433480研究中心III期2022-05 启动
  11. A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)已终止NCT04740918研究中心III期2021-06 启动
  12. Breast Mesh Used in Two-staged Breast Reconstruction状态不明NCT04967976研究中心不分期2021-08 启动
  13. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  14. Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)进行中,不再招募NCT03725059研究中心III期2018-12 启动
  15. Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women状态不明NCT02914158研究中心III期2016-03 启动
  16. Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients状态不明NCT02062489研究中心III期2014-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.3%。

牵头论文
24
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 2220232024: 5520242025: 772025

杭州有 9 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
    分期
    未注明
    开始
    2025-06
    发布
    登记号
    NCT06939400

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江省人民医院杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经外科病理/检验科影像/核医学科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文24
  1. Metalloporphyrin organic framework oxygen-generators enable tumour-targeted photodynamic therapy and metabolic reprogramming for enhanced glioblastoma treatment.2026Journal of colloid and interface science
  2. Biomimetic platinum-based nanoplatform for photoacoustic imaging-guided multimodal glioblastoma therapy.2026Journal of colloid and interface science
  3. Integration of Single-Cell and Bulk RNA-seq Data to Identify the Cancer-Associated Fibroblast Subtypes and Risk Model in Glioma.2025Biochemical genetics
  4. Novel Insights Into Small Open Reading Frame-Encoded Micropeptides in Glioblastoma.2025Cell biology international
  5. Mechanistic Insights into the Anti-Glioma Effects of Exosome-Like Nanoparticles Derived from Garcinia Mangostana L.: A Metabolomics, Network Pharmacology, and Experimental Study.2025International journal of nanomedicine免费全文
  6. ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy.2025Journal of controlled release : official journal of the Controlled Release Society
  7. Exosomal circ_0001583 Drives Glioblastoma Cell Advancement Through the miR-647/CKAP2L Pathway.2025Molecular neurobiology免费全文
  8. Three Decades of Photodynamic Therapy for Glioblastoma: A Comprehensive Scientometric Analysis.2025Photodiagnosis and photodynamic therapy
  9. Glioma stem cells: drivers of tumor progression and recurrence.2025Stem cell research & therapy免费全文
  10. β-Mangostin targets and suppresses glioma via STING activation and tumor-associated microglia polarization.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.2024CNS neuroscience & therapeutics免费全文
  12. Inhibition of circular JUN prevents the proliferation and invasion of glioblastoma via miR-3064-IGFBP5 axis.2024Journal of cellular and molecular medicine免费全文
  13. The Implication of Photodynamic Therapy Applied to the Level of Tumor Resection on Postoperative Cerebral Edema and Intracranial Pressure Changes in Gliomas.2024Lasers in surgery and medicine
  14. Turning attention to tumor-host interface and focus on the peritumoral heterogeneity of glioblastoma.2024Nature communications免费全文
  15. EGFR-Induced and c-Src-Mediated CD47 Phosphorylation Inhibits TRIM21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  16. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.2023Journal of molecular neuroscience : MN
  17. NIR-II absorptive dithienopyrrole-thiadiazolobenzotriazole conjugated polymer for photoacoustic imaging-guided glioblastoma multiforme photothermal therapy.2022Acta biomaterialia
  18. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers.2022Drug delivery免费全文
  19. IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma.2022Frontiers in endocrinology免费全文
  20. Inhibition of hypoxia-inducible factor 1 by acriflavine renders glioblastoma sensitive for photodynamic therapy.2022Journal of photochemistry and photobiology. B, Biology
  21. TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells.2022Redox biology免费全文
  22. Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.2021Bioscience trends
  23. Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.2021International journal of nanomedicine免费全文
  24. The Nomogram of MRI-based Radiomics with Complementary Visual Features by Machine Learning Improves Stratification of Glioblastoma Patients: A Multicenter Study.2021Journal of magnetic resonance imaging : JMRI
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence即将招募NCT06939400牵头方2025-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年没有牵头视网膜母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. miR-140-5p suppresses retinoblastoma cell proliferation, migration, and invasion by targeting CEMIP and CADM3.2018Cellular and molecular biology (Noisy-le-Grand, France)

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

杭州有 8 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

杭州有 6 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    分期
    I期
    开始
    2025-05
    发布
    登记号
    NCT06926283

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Clinicopathologic and molecular characteristics of malignant gastrointestinal neuroectodermal tumors].2017Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors正在招募NCT06926283研究中心I期2025-05 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 3320222023: 0020232024: 2220242025: 332025

杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层双抗与抗体药物复发与耐药
论文中的科室病理/检验科
牵头的论文10
  1. Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.2025Cellular and molecular life sciences : CMLS免费全文
  2. Performance and comparison of FLCCheck: a novel serum free light chain assay for the Auxiliary Diagnosis of Multiple Myeloma.2025European journal of medical research免费全文
  3. Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.2025Scientific reports免费全文
  4. Regarding the prognostic role of vitamin D deficiency in a Japanese multiple myeloma study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Immunoglobulin Replacement Therapy for Hypogammaglobulinemia in Multiple Myeloma Should Not Be Ignored.2024Turkish journal of haematology : official journal of Turkish Society of Haematology免费全文
  6. Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.2022Clinica chimica acta; international journal of clinical chemistry
  7. Role of Tfh17 cells in patients with multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  8. A patient with hypercalcemia and hyperparathyroidism due to adenoma mimicking multiple myeloma.2022International journal of laboratory hematology
  9. Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  10. Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  2. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma已完成NCT05376345研究中心I期2022-09 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.4%。

牵头论文
15
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 5520222023: 1120232024: 4420242025: 332025

杭州有 8 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    分期
    II期
    开始
    2024-07
    发布
    登记号
    NCT06534762

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:浙江省人民医院杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科
牵头的论文15
  1. Tumor Pro-Senescence Strategy to Enhance Mild Photothermal Therapy of Diffuse Large B-Cell Lymphoma.2025ACS applied materials & interfaces
  2. Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.2025Biology direct免费全文
  3. Causal association between endocrine diseases and lymphoid malignancies explored through two-sample Mendelian randomization analysis.2025Scientific reports免费全文
  4. C-MYC-activated lncRNA SNHG20 accelerates the proliferation of diffuse large B cell lymphoma via USP14-mediated deubiquitination of β-catenin.2024Biology direct免费全文
  5. Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. TNFAIP3 Overexpression Inhibits Diffuse Large B-Cell Lymphoma Progression by Promoting Autophagy through TLR4/MyD88/NF-κB Signaling Pathway.2024Discovery medicine
  7. Importance of Rare Gene Alterations in the Prognosis of B-Cell Acute Lymphoblastic Leukemia.2024Turkish journal of haematology : official journal of Turkish Society of Haematology免费全文
  8. A patient with the highly suspected B cell lymphoma accompanied by the erythrocytes cold agglutination: Case report.2023Medicine免费全文
  9. Use of Ultrasound to Observe Mycosis Fungoides: A Case Report and Review of Literature.2022Current medical imaging
  10. Primary pulmonary mucosa-associated lymphoid tissue lymphoma with radiological presentation of middle lobe syndrome diagnosed by bronchoscopy: a case report.2022Hong Kong medical journal = Xianggang yi xue za zhi
  11. Caution the difference between the atypical lymphocyte with circulating Hodgkin lymphoma cells.2022International journal of laboratory hematology
  12. Pericardial involvement in a common B-cell acute lymphoblastic leukemia patient.2022International journal of laboratory hematology
  13. New-onset Systemic Lupus Erythematosus in a Woman with Previous Lymphoma during Late Pregnancy: a case report and literature review.2022Iranian journal of immunology : IJI
  14. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.2021Bioscience reports免费全文
  15. Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo.2021Oncology reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study正在招募NCT06534762牵头方II期2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

杭州有 6 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题抗体与诊断
论文中的科室风湿免疫科神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.2%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 3320232024: 3320242025: 442025

杭州有 11 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    分期
    II期
    开始
    2026-07
    发布
    登记号
    NCT07521007

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、兰州、北京、合肥、哈尔滨、天津、广州、成都、杭州、武汉、福州、苏州、西安、长春、长沙

  2. 正在招募
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    分期
    IV期
    开始
    2025-11
    发布
    登记号
    NCT07110415

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肾内科
牵头的论文12
  1. The relationship between Non-HDL/HDL ratio and in-stent restenosis in patients with coronary artery atherosclerosis after percutaneous coronary intervention.2025BMC cardiovascular disorders免费全文
  2. Underlining the Molecular Mechanism of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in Lipid Metabolism by Combining Multiple Sets of Data Sets.2025IUBMB life免费全文
  3. Association of 24-Hour blood pressure average real variability with poor prognosis in critically ill patients with coronary artery disease.2025Scientific reports免费全文
  4. Serum Angptl2 and CyPA Levels in Acute Myocardial Infarction and In-Stent Restenosis After Percutaneous Coronary Intervention: A Single-Center Retrospective Case-Control Study.2025Vascular health and risk management免费全文
  5. Coronary artery calcium scoring assessment in ultra-low-dose chest computed tomography.2024Clinical imaging
  6. Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.2024Global heart免费全文
  7. Spontaneous multivessel coronary artery spasm: a case report.2024The Journal of invasive cardiology
  8. Lower Baseline LDL Cholesterol Affects All-cause Mortality in Patients with First Percutaneous Coronary Intervention.2023Biomedical and environmental sciences : BES
  9. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.2023Coronary artery disease免费全文
  10. Coronary computed tomography angiography imaging features combined with computed tomography-fractional flow reserve, pericoronary fat attenuation index, and radiomics for the prediction of myocardial ischemia.2023Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  11. Coronary artery calcification in patients with advanced chronic kidney disease.2022BMC cardiovascular disorders免费全文
  12. Predicting Chronic Myocardial Ischemia Using CCTA-Based Radiomics Machine Learning Nomogram.2022Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction状态不明NCT02641184牵头方2015-12 启动
  2. A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis正在招募NCT07521007研究中心II期2026-07 启动
  3. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction正在招募NCT07110415研究中心IV期2025-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

杭州有 9 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊柱侧弯

Scoliosis

2021–2025 年中国大陆作者发表的 925 篇脊柱侧弯 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 6 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
    分期
    不分期
    开始
    2025-03
    发布
    登记号
    NCT06314594

    年龄 12 岁 至 16 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
牵头的论文1
  1. Status and frontiers of Fabre disease.2025Orphanet journal of rare diseases免费全文
早期论文(2016–2020 年)1
  1. Coexistence of Fabry disease with IgM nephropathy: A case report.2019Medicine

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年没有牵头杜氏肌营养不良的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing.2020BioMed research international

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文4
  1. Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.2025Renal failure免费全文
  2. A patient report scale research to access the symptom burden in patients with IgA nephropathy.2024Scientific reports免费全文
  3. Oral Methylprednisolone and Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy.2022JAMA
  4. Mesangial Cell-Derived Exosomal miR-4455 Induces Podocyte Injury in IgA Nephropathy by Targeting ULK2.2022Oxidative medicine and cellular longevity免费全文
早期论文(2016–2020 年)2
  1. iTRAQ-based comparative proteomics analysis reveals specific urinary biomarkers for various kidney diseases.2020Biomarkers in medicine
  2. How many podocyte autophagosomes are there in immunoglobulin A nephropathy and idiopathic membranous nephropathy?2016International urology and nephrology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. MYTP01 for Immune-Mediated Diseases即将招募NCT07901764牵头方不分期2026-12 启动
  2. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases即将招募NCT06774664研究中心I/II期2025-01 启动
  3. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动
  4. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  5. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  6. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动
  7. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.3%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 3320242025: 002025

杭州有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室风湿免疫科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

杭州有 6 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

浙江省人民医院

Zhejiang Provincial People's Hospital

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Zhejiang Provincial People's Hospital (Affiliated People's Hospital); Zhejiang Provincial People's Hospital (Affiliated People's Hospital; Zhejiang Provincial People's Hospital(Affiliated People's Hospital); Zhejiang Provincial People's Hospital Chun'an Branch; Zhejiang Provincial People's hospital; Zhejiang Provincial People's Hospital Bijie Hospital; Affiliated Zhejiang Provincial People's Hospital; Zhejiang Provincial People' s Hospital

提出更正下载数据